Dr. Giermasz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Stockton Blvd Suite 202
Sacramento, CA 95817Phone+1 916-734-3461Fax+1 916-734-3591
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2008 - 2011
UPMC Medical EducationResidency, Internal Medicine, 2005 - 2008
Medical University of WarsawClass of 1998
Certifications & Licensure
CA State Medical License 2008 - 2026
PA State Medical License 2005 - 2008
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.Amy Dunn, Yesim Dargaud, Yasmina Abajas, Manuel Carcao, Giancarlo Castaman
Haemophilia. 2025-01-01 - Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial.Andrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V Quon
Research and Practice in Thrombosis and Haemostasis. 2024-11-01 - 8 citationsGiroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington
Blood. 2024-02-29
Abstracts/Posters
- Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patien...Adam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 YearAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia BAdam Giermasz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
